Therapie des Typ-2-Diabetes – Zielwerterreichung unter Vermeidung von Nebenwirkungen

In diesem kurzen Übersichtsartikel soll auf die Bedeutung der antihyperglykämischen Therapie beim Typ-2-Diabetes eingegangen werden. Insbesondere stehen dabei die Ergebnisse der großen Diabetes-Endpunktstudien der letzten Jahre sowie die neue evidenzbasierte Leitlinie der Deutschen Diabetes-Gesellschaft im Fokus, die eine sichere Therapiezielerreichung unter Vermeidung von Hypoglykämien sowie einer ausgeprägten Gewichtszunahme anstreben.

This brief review stresses the significance of anti-hyperglycaemic therapy in cases of type 2 diabetes. Focus is especially on the results of the large-scale Diabetes Final Stage Studies conducted during the past few years and on the new evidence-based guideline compiled by the German Diabetes Association. These efforts have been especially directed at a safe therapy target while avoiding hypoglycaemias and any pronounced increase in body weight.

Key words

Type 2 diabetes - how to arrive at the therapy target - avoidance of hypoglycaemias - evidence-based guidelines by the German Diabetes Association

Literatur

• 1 Gaede P, Andersen HL, Parving HH, Pedersen O.. Effect of a Multifactorial intervention on Mortality in Type Diabetes.  N Engl J Med. 2008;  358 580-591
• 2 Duckworth W, Abraira C, Moritz T et al.. VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes.  N Engl J Med. 2009;  360 129-139
• 3 The Action to Control Cardiovascular Risk in Diabetes Study Group. . Effect of Intensive Glucose Lowering in Type 2 Diabetes.  N Eng J Med. 2008;  358 2545-2559
• 4 The ADVANCE Collaborative Group. . Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes.  N Eng J Med. 2008;  358 2560-2572
• 5 Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA.. 10-year follow-up of intensive glucose control in type 2 diabetes.  N Engl J Med. 2008;  359 1577-1589
• 6 Matthaei S, Bierwirth R, Fritsche A et al.. Medikamentöse antihyperglykämische Therapie des Diabetes mellitus Typ 2 – Update der evidenzbasierten Leitlinie der Deutschen Diabetes-Gesellschaft.  Diabetologie. 2009;  4 32-64
• 7 Holman RR, Farmer AJ, Davies MJ et al.. Three-year efficacy of complex insulin regimens in type 2 diabetes.  N Engl J Med. 2009;  361 1736-1747
• 8 Horvath K, Jeitler K, Berghold A et al.. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus (Review).  Cochrane Database of systematic Review. 2 CD 005613 2007; 
• 9 Bolen S, Feldman L, Vassy J et al.. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus.  Ann Int Med. 2007;  147 386-399
• 10 Leese GP, Wang J, Broomhall J et al.. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population based-study of health service resource use.  Diabetes Care. 2003;  26 1176-1180
• 11 UK Hypoglycemia Study Group. . Risk of hypoglycemia in types 1 and 2 diabetes: effects of treatment modalities and their duration.  Diabetologia. 2007;  50 1140-1147
• 12 UK Prospective Diabetes Study (UKPDS) Group. . Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type-2 diabetes. (UKPDS 33).  Lancet. 1998;  352 837-853
• 13 UKPDS Group. . Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).  Lancet. 1998;  352 854-865
• 14 Del Prato S, Felton AM, Munro N et al.. Improving glucose management: ten steps to get more patients with type diabetes to glycaemic goal.  Int J Clin Pract. 2005;  59 1345-1355
• 15 Del Prato S.. Megatrials in type 2 diabetes. From excitement to frustration?.  Diabetologia. 2009;  52 1219-1226

Korrespondenz